




Organization **IC1600** Bldg./Room **1600**  
U. S. DEPARTMENT OF COMMERCE  
COMMISSIONER FOR PATENTS  
P.O. BOX 1450  
ALEXANDRIA, VA 22313-1450  
IF UNDELIVERABLE RETURN IN TEN DAYS  
OFFICIAL BUSINESS



AN EQUAL OPPORTUNITY EMPLOYER

FOLECO 943063021 1A04 12 03/15/06  
FORWARD TIME EXP RTN TO SEND  
FOLEY & LARDNER LLP  
1530 PAGE MILL RD  
PALO ALTO CA 94304-1125

RETURN TO SENDER



BEST AVAILABLE COPY

Handwritten initials: JFJ



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/621,958	07/16/2003	Steven J. Locke	570002000100	2039

7590 03/08/2006  
Gerald F. Swiss  
Foley & Lardner LLP  
Three Palo Alto Square  
3000 El Camino Real, Suite 100  
Palo Alto, CA 94306-2121



EXAMINER

VENCI, DAVID J

ART UNIT PAPER NUMBER

1641

DATE MAILED: 03/08/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/621,958	LOCKE ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	David J. Venci	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on December 2, 2005.
- 2a) ☐ This action is FINAL.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1-31 is/are pending in the application.
- 4a) Of the above claim(s) 28 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-27 and 29-31 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-31 are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |                                                                                                                                               |                                                                                         |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                                                   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                                          | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>10/31/05</u> . | 6) <input type="checkbox"/> Other: _____                                                |

Art Unit: 1641

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on December 2, 2005, is entered. Applicants amend claims 1-9, 11-13, 15-21 and 23-29, and add new claims 30-31.

Currently, claims 1-27 and 29-31 are under examination. Claim 28 is directed to a non-elected invention and was withdrawn from consideration in the Office Action of December 28, 2004.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### ***Information Disclosure Statement***

The information disclosure statement filed October 31, 2005, fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each cited foreign patent document. Specifically, Examiner is unable to locate a copy of WO 2003/050544 in the application file. The information referenced in WO 2003/050544 has not been considered.

Art Unit: 1641

***Claim Rejections - 35 USC § 101***

Claims 27 and 30-31 are rejected under 35 U.S.C. 101 because the claimed recitation of a use results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd. v. Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Art Unit: 1641

***Claim Rejections - 35 USC § 112 – first paragraph***

Claims 1-27 and 29 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claims contain subject matter that was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Examiner is unable to locate in the specification the following claim limitations:

In claims 1-3, 24-27 and 29-31:

The object(s) consisting or comprising an “affinity group”

The object(s) and/or step(s) required for “use of an affinity group”

The negative limitation “without use of an affinity group”

The object(s) and/or step(s) required for labeling “without use of an affinity group”

In claims 1-3, 27 and 29-31:

The object(s) and/or step(s) required for satisfaction of the condition wherein “molecules are derivatized prior to analysis”

In claim 29:

A method for the quantitative analysis of two or more “derivatives”

Applicants are required to cancel the new matter in response to this Office Action.<sup>1</sup>

---

<sup>1</sup> Applicants are advised that, upon cancellation of the new matter, Examiner may revert to rejection of the amended claims using prior grounds for rejection in view of *Aebersold et al.* (US 6,670,194), *Figeys et al.* (US 2002/0076817) and *Vandekerckhove & Gevaert* (US 2004/0005633) as set forth in the prior Office Action.

***Claim Rejections - 35 USC § 112 – second paragraph***

Claims 1-27 and 29 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The specific claim rejections under 35 USC 112, second paragraph set forth, *infra*, are considered relevant to other claims not explicitly mentioned, as deemed reasonably appropriate.

In claims 1-3, 27 and 29-31, the passive voice recitation "the molecules are derivatized" is indefinite. The identity of object(s) and/or step(s), if any, required for performing derivatization is/are not clear. Whether the act or process of derivatization is completed or performed, or merely intended, is not clear.

In claims 1-3, 27 and 29-31, the recitation of "derivatized prior to analysis" is indefinite. The identity of object(s) and/or step(s) required for satisfaction of the condition wherein "molecules are derivatized prior to analysis" is not clear.

In claims 1-3, 24-27 and 29-31, the passive voice recitation "the reagents are labeled" is indefinite. The identity of object(s) and/or step(s), if any, required for performing labeling is/are not clear. The identity of the label(s) for labeling "the reagents" is not clear. Whether "the reagents" are labeled with "differential isotope labeled reagents" is not clear. The overall purpose of labeling "the reagents" with "differential isotope labeled reagents" is not clear.

In claims 1-3, 24-27 and 29-31, the recitation of "affinity group" is indefinite. The identity of object(s) consisting or comprising an "affinity group" is not clear.

Art Unit: 1641

In claims 1-3, 24-27 and 29-31, the recitation of "use of an affinity group" is indefinite. The identity of object(s) and/or step(s) required for "use of an affinity group" is not clear. The identity of object(s) and/or step(s) required for labeling "without use of an affinity group" is not clear.

In claims 1-3, 24-27 and 29-31, the phrase "the reagents" lacks antecedent basis.

In claims 1-3, 24-27 and 29-31, the phrase "the molecules" lacks antecedent basis.

In claims 1 and 27, the prepositional phrase "with at least two differential isotope labeled reagents" is indefinite. The object(s) of said prepositional phrase is/are not clear. Whether said prepositional phrase modifies "reacting" and/or "molecules" and/or "sample" is not clear.

In claims 1, 3, 24, 26-27, 29 and 31, the recitation of "differential isotope labeled reagents" is indefinite. The number of chemically distinct reagents is not clear. The number of isotopically distinct reagents is not clear.

In claims 1 and 27, the recitation of the phrase "wherein the differential isotope labeled reagents result in differential isotope labeled derivatives" is indefinite. How one noun can "result" in another noun is not clear.

In claims 2 and 30, the prepositional phrase "with isotope labeled reagents" is indefinite. The object(s) of said prepositional phrase is/are not clear. Whether said prepositional phrase modifies "reacting" and/or "molecules" is not clear.

In claims 3 and 31, the prepositional phrase "with differential isotope labeled reagents" is indefinite. The object(s) of said prepositional phrase is/are not clear. Whether said prepositional phrase modifies "reacting" and/or "molecules" and/or "sample" is not clear.



Art Unit: 1641

In claims 3, the recitation of the phrase "wherein the differential isotope labeled reagents result in a reductive alkylation" is indefinite. How one noun can "result" in another noun is not clear.

In claim 5, the recitation of "the step of reacting the molecules with differential isotope labeled reagents" lacks antecedent basis in claim 2.

In claim 15, the recitation of "the differential isotope labeled reagents" lacks antecedent basis in claim 2.

In claim 24, the prepositional phrase "with the molecules" is indefinite. The object(s) of said prepositional phrase is/are not clear. Whether said prepositional phrase modifies "reaction" and/or "reagents" is not clear.

In claims 25-26, the prepositional phrase "for quantitative analysis by mass spectroscopy" appears grammatically misplaced. The object(s) of said prepositional phrase is/are not clear.

In claims 25-26 and 29, the recitation of "the molecules" lacks antecedent basis.

In claim 25, the recitation of "to alkylamine derivatives" and "by isotopically labeled reagents" appear grammatically misplaced. The object(s) of each phrase is/are not clear.

In claim 26, the recitation of the phrase "by differential isotope labeled reagents" appears grammatically misplaced. The object(s) of the phrase is/are not clear.

In claims 27 and 30-31, the preamble recitation of "[u]se of a mass spectrometer" is indefinite. The field(s) of art encompassed by said "[u]se" is/are not clear. The term "use" is neither defined in Applicants' specification nor is the term applied to Applicants' invention in the context of a "[u]se of a

Art Unit: 1641

mass spectrometer". Whether Applicants' "use" is capable of establishing a basis for distinguishing Applicants' invention over the prior art is not clear.

In claim 29, the prepositional phrase "with differential isotope labeled reagents" is indefinite. The object(s) of said prepositional phrase is/are not clear. Whether said prepositional phrase modifies "reacting" and/or "molecules" and/or "extracts" is not clear.

Art Unit: 1641

***Claim Rejections - 35 USC § 102***

Claims 2-6, 8-15, 17-23, 25-26 and 29-31 are rejected under 35 U.S.C. 102(e) as being anticipated by Aebersold *et al.* (US 6,670,194).

Aebersold *et al.* teach a method for the quantitative analysis (see Title, "Quantitative Analysis") of a sample of molecules (see col. 11, lines 35-39, "two or more protein samples", lines 47-54, "cell homogenates; cell fractions; biological fluids..." etc.) having an amine (see col. 10, lines 30-41, "PRGs... include... those that react with amino groups") bearing an active hydrogen comprising the steps of:

reacting the molecules with isotope labeled reagents (see col. 11, lines 35-39, "the proteins in each sample are reacted with affinity tagging reagents which are substantially chemically identical but differentially isotopically labeled") resulting in the reductive alkylation of the amines (see col. 10, lines 50-52, "amino reactive groups include aldehydes... in the presence... of NaBH<sub>4</sub> or NaCNBH<sub>4</sub>") to their alkylamine derivatives, such that the alkylamine derivatives are isotopically labeled (see Abstract, "The linker may be differentially isotopically labeled"), and

examining the derivative by mass spectrometry (see Abstract, "reaction products are characterized by mass spectrometric (MS) techniques").

Examiner posits that Aebersold *et al.* explicitly teach a reaction of aldehydes (belonging to the PRGs) and amino groups (belonging to sample proteins) in the presence of NaBH<sub>4</sub> or NaCNBH<sub>4</sub>. Consequently, the claimed "amine bearing an active hydrogen" and "alkylamine derivatives" necessarily result from this teaching of Aebersold *et al.* and would be so recognized by persons of ordinary skill in the art.

With respect to claims 3 and 29, Aebersold *et al.* teach a method for the quantitative analysis of two or more samples (see col. 11, lines 35-39, "two or more protein samples", lines 47-54, "cell homogenates;

Art Unit: 1641

cell fractions; biological fluids..." etc.). In addition, Aebersold *et al.* teach the step of combining the derivatized molecules (see col. 6, lines 2-3, "The treated samples are then combined").

With respect to claims 4 and 29, Aebersold *et al.* teach a method comprising an additional step of cleaving the derivatized molecules prior to examining by mass spectrometry (see col. 6, lines 3-4).

With respect to claim 5, Aebersold *et al.* teach a method comprising an additional step of denaturing the molecules prior to reacting with isotopically labeled reagents (see col. 12, line 4-6).

With respect to claim 6, Aebersold *et al.* teach a method wherein electrospray ionization is used (see col. 11, lines 58-59).

With respect to claims 8-9, 11 and 29, Aebersold *et al.* teach a method comprising an additional step of separating derivatized molecules by 1D gel electrophoresis, 2D gel electrophoresis, or HPLC before examining by mass spectrometry (see col. 36, lines 11-12).

With respect to claim 10, Aebersold *et al.* teach a method comprising an additional step of separating the fragments after cleaving (see col. 19, lines 41-43).

With respect to claims 12-14 and 29, Aebersold *et al.* teach a method comprising an additional step of analyzing the preparation by CID in MS/MS mode to sequence the molecule (see col. 36, lines 19-36).

With respect to claims 15 and 17, Aebersold *et al.* teach a method wherein the isotopically labeled reagents are an aldehyde and a sodium borohydride reducing agent (see col. 10, lines 50-52).

With respect to claims 18-19 and 29, Aebersold *et al.* teach a method wherein the sample proteins are extracted from cells (see col. 5, line 63, "cell or tissue lysates").

Art Unit: 1641

With respect to claim 20, Aebersold *et al.* teach a method wherein the amines are lysine residues and N-terminal amino groups (see col. 18, lines 11-12).

With respect to claims 21-23, Aebersold *et al.* teach a method wherein an electrospray ionization ion trap spectrometer is used (see col. 22, lines 29-30).

With respect to claim 25, Aebersold *et al.* describe a preparation of a sample (see col. 11, lines 35-39, "two or more protein samples", lines 47-54, "cell homogenates; cell fractions; biological fluids..." etc.) comprising isotopically labeled derivatives (see Abstract, "The linker may be differentially isotopically labeled") having an amine (see col. 10, lines 30-41, "PRGs... include... those that react with amino groups") bearing an active hydrogen, resulting from the reductive alkylation of the amines (see col. 10, lines 50-52, "amino reactive groups include aldehydes... in the presence... of  $\text{NaBH}_4$  or  $\text{NaCNBH}_4$ ") to their alkylamine derivatives. The claimed "alkylamine derivatives" necessarily results from the aforementioned teaching of Aebersold *et al.* and would be so recognized by persons of ordinary skill in the art.

With respect to claim 27, Aebersold *et al.* describe a method comprising a mass spectrometer (see Abstract).

Art Unit: 1641

***Claim Rejections - 35 USC § 103***

Claims 1, 4-15, 17-24 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Aebersold *et al.* (US 6,670,194) in view of Figeys *et al.* (US 2002/0076817).

Aebersold *et al.* teach a method for the simultaneous (see col. 11, line 40, "The samples are combined and processed as one") quantitative analysis (see Title, "Quantitative Analysis") of at least three samples (see col. 11, lines 35-39, "two or more protein samples", lines 47-54, "cell homogenates; cell fractions; biological fluids..." etc.) comprising the steps of:

reacting each sample with differential isotope labeled reagents (see col. 11, lines 35-39, "the proteins in each sample are reacted with affinity tagging reagents which are substantially chemically identical but differentially isotopically labeled") wherein the reagents are labeled (see col. 11, lines 35-39, "affinity tagging reagents are... differentially isotopically labeled"),

combining the derivatives (see col. 6, lines 2-3, "The treated samples are then combined"), and

examining the derivatives by mass spectrometry (see Abstract, "reaction products are characterized by mass spectrometric (MS) techniques").

Aebersold *et al.* do not teach the step of "reacting the molecules of each sample with at least two differential isotope labeled reagents."

However, Figeys *et al.* teach the step of reacting each sample with two differential isotope labeled reagents (see Fig. 6, " $O^{16}$ -water" and " $O^{18}$ -water") (see Fig. 6, "Peptides mixture") in order to label individual samples with distinct isotope ratios (see para. [0010]).

Art Unit: 1641

It would have been obvious for a person of ordinary skill in the art to modify the simultaneous quantitative method of Aebersold *et al.* with the use of two isotopically labeled reagents because Figeys *et al.* teach that labeling individual samples with distinct isotope ratios allows a convenient means for "sample tracking" which allows a peptide to be traced back to its sample source (see para. [0036]).

With respect to claim 4-6, 8-15, 17-23 and 27, see *supra*.

With respect to claim 7, Figeys *et al.* teach a method wherein ionspray is used (see para. [0055]).

With respect to claims 24, Figeys *et al.* teach the step of reacting each sample with two differential isotope labeled reagents (see Fig. 6, "O<sup>16</sup>-water" and "O<sup>18</sup>-water") (see Fig. 6, "Peptides mixture").

---

Claim 16 is rejected under 35 U.S.C. 103(a) as being unpatentable over Aebersold *et al.* (US 6,670,194) and Figeys *et al.* (US 2002/0076817) as applied to claims 1 and 15, and further in view of Vandekerckhove & Gevaert (US 2004/0005633).

Aebersold *et al.* and Figeys *et al.* teach a method for the simultaneous quantitative analysis of at least three samples as substantially described, *supra*, and incorporated herein.

Aebersold *et al.* and Figeys *et al.* do not teach a method wherein formaldehyde and acetaldehyde are used.

However, Vandekerckhove & Gevaert teach the use of deuterated formaldehyde and acetaldehyde (see para. [0107]) in order to induce a distinguishable mass shift in peptide analysis.

Art Unit: 1641

It would have been obvious for a person of ordinary skill in the art to modify the method of Aebersold *et al.* and Figeys *et al.* with the use of formaldehyde and acetaldehyde because Vandekerckhove & Gevaert teach that such reactions are "known to proceed in mild conditions" and "may lead to the incorporation of a predictable number of deuterium atoms" (see para. [0107]).



**Response to Arguments**

In prior Office Action, claims 1-27 and 29 were rejected under 35 U.S.C. 102(e) or 35 U.S.C. 103(a) in view of various combinations of teachings of Aebersold *et al.* (US 6,670,194), Figeys *et al.* (US 2002/0076817) and Vandekerckhove & Gevaert (US 2004/0005633).

In response, Applicants amend independent claims 1-3, 24-27 and 29-31 to add the new limitation of reagents "labeled without use of an affinity group". Applicants attempt to distinguish their claimed invention from that of Aebersold *et al.* by alleging that Applicants' invention is "a one component system" that combines an isotope label group (L) with a covalent attachment group (A) into a single molecule (see Applicants' reply, paragraph bridging pp. 13-14), whereas Aebersold *et al.* describe a "multi-component" reagent (see Applicants' reply, p. 13, fifth paragraph). Finally, Applicants posit that the present invention "involves placement of deuterium and/or carbon-13 in methyl amine (N-(CH<sub>3</sub>)<sub>2</sub> or N-(CD<sub>3</sub>)<sub>2</sub>)" (see Applicants' reply, p. 14, first full paragraph and paragraph bridging pp. 14-15).

Applicants' arguments have been carefully considered but are not persuasive.

Notwithstanding issues of new matter and indefiniteness, set forth *supra*, *Claim Rejections - 35 USC § 112 – first paragraph*, and *Claim Rejections - 35 USC § 112 – second paragraph*, respectively, Examiner interprets said reagent "labeled without use of an affinity group" as a reagent that is labeled with a label (L) without any intervening affinity group.

The new claim limitation of reagents "labeled without use of an affinity group" is not sufficient to overcome anticipation by Aebersold *et al.* because Aebersold *et al.* also describe an isotope labeled reagent (see col. 4, line 6, "A—L—PRG") wherein the reagent (PRG) is labeled with a label (L) without any intervening affinity group.

Art Unit: 1641

Applicants attempt to distinguish their claimed invention from that of Aebersold *et al.* by alleging that Applicants' invention is "a one component system", whereas Aebersold *et al.* describe a "multi-component" reagent is not persuasive because Aebersold *et al.* also describe "a one component system" (see col. 4, line 6, "A—L—PRG") that combines an isotope label group (L) with a covalent attachment group (A) into a single molecule (A—L—PRG). The mere fact that Aebersold *et al.* characterize said single molecule using the alphanumeric symbols A—L—PRG does not detract from the reality that Aebersold *et al.* also describe "a one component system" (see col. 4, line 6, "A—L—PRG") that combines an isotope label group (L) with a covalent attachment group (A) into a single molecule (A—L—PRG).

Applicants' arguments directed to the position that the present invention "involves placement of deuterium and/or carbon-13 in methyl amine ( $N-(CH_3)_2$  or  $N-(CD_3)_2$ " is not persuasive because Applicants appear to rely upon limitations that do not appear in the rejected claims. Although claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993).

Art Unit: 1641

**Conclusion**

No claims are allowed at this time.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Venci whose telephone number is 571-272-2879. The examiner can normally be reached on 08:00 - 16:30 (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

David J Venci  
Examiner  
Art Unit 1641

djv

*Christopher L. Chin*  
CHRISTOPHER L. CHIN  
PRIMARY EXAMINER  
GROUP ~~1800~~ 1641  
3/3/06

Substitute for form 1449B/PTO  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

<b>Application Number</b>	10/621,958
<b>Filing Date</b>	7/16/2003
<b>First Named Inventor</b>	Steven J. LOCKE
<b>Group Art Unit</b>	1641
<b>Examiner Name</b>	David J. Venci
<b>Attorney Docket Number</b>	357000-1200

1

of

3

[illegible][illegible]

Dir Verni

2/27/06

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

COPY

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/621,958
Date Submitted: May 6, 2005		Filing Date	7/16/2003
(use as many sheets as necessary)		First Named Inventor	Steven J. LOCKE
		Group Art Unit	1641
		Examiner Name	David J. Venci
		Attorney Docket Number	357000-1200
Sheet	3	of	3

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
DV	C14	Goshe et al. "Phosphoprotein Isotope-Coded Affinity Tag Approach for Isolating and Quantitating Phosphopeptides in Proteome-Wide Analyses" <i>Anal. Chem.</i> 73:2578-2586 (2001)	
	C15	Molloy et al. "Phosphopeptide Derivatization Signatures To Identify Serine and Threonine Phosphorylated Peptides by Mass Spectrometry" <i>Anal. Chem.</i> 73:5387-5394 (2001)	
	C16	Gygi et al. "Quantitative analysis of complex protein mixtures using isotope-coded affinity tags" <i>Nature Biotech.</i> 17:994-999 (1999)	
	C17	Oda et al. "Accurate quantitation of protein expression and site-specific phosphorylation" <i>Proc. Natl. Acad. Sci. USA</i> 96:6591-6596 (1999)	
	C18	Goodlett et al. "Differential stable isotope labeling of peptides for quantitation and <i>de novo</i> sequence derivation" <i>Rapid Commun. Mass Spectrom.</i> 15:1214-1221 (2001)	
↓	C19	Mirgorodskaya et al. "Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using <sup>18</sup> O-labeled internal standards" <i>Rapid Commun. Mass Spectrom.</i> 14:1226-1232 (2000)	

Examiner Signature	<i>D. Venci</i>	Date Considered	2/27/06
--------------------	-----------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

COPY

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> Date Submitted: May 6, 2005 (use as many sheets as necessary)		Application Number	10/621,958
		Filing Date	7/16/2003
		First Named Inventor	Steven J. LOCKE
		Group Art Unit	1641
		Examiner Name	David J. Venci
Sheet	2	of	3
		Attorney Docket Number	357000-1200

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
✓	C1	Heller, et al. "Synthesis of Biologically Active Tritiated Amylin and Salmon Calcitonin Analogues" <i>Analytical Biochemistry</i> 285:100-104 (2000)	
	C2	Sechi et al. "Modification of Cysteine Residues by Alkylation. A Tool in Peptide Mapping and Protein Identification" <i>Anal. Chem</i> 70:5150-5158 (1998)	
	C3	Cahill et al. "Analysis of relative isotopologue abundances for quantitative profiling of complex protein mixtures labeled with the acrylamide/D <sub>3</sub> -acrylamide alkylation tag system" <i>Rapid Commun. Mass Spectrom.</i> 17:1283-1290 (2003)	
	C4	Gehanne et al. "Quantitative analysis of two-dimensional gel-separated proteins using isotopically marked alkylating agents and matrix-assisted laser desorption/ionization mass spectrometry" <i>Rapid Commun. Mass Spectrom.</i> 16:1692-1698 (2002)	
	C5	Hsu et al. "Stable-Isotope Dimethyl Labeling for Quantitative Proteomics" <i>Anal. Chem.</i> 75:6843-6852 (2003)	
	C6	Munchbach et al. "Quantitation and Facilitated de Novo Sequencing of Proteins by Isotopic N-Terminal Labeling of Peptides with a Fragmentation-Directing Moiety" <i>Anal. Chem.</i> 72:4047-4057 (2000)	
	C7	Smith et al. "Rapid quantitative measurements of proteomes by Fourier transform ion cyclotron resonance mass spectrometry" <i>Electrophoresis</i> 22:1652-1668 (2001)	
	C8	Weckwerth et al. "Comparative quantification and identification of phosphoproteins using stable isotope labeling and liquid chromatography/mass spectrometry" <i>Rapid Commun. Mass Spectrom.</i> 14:1677-1681 (2000)	
	C9	Ji et al. "Strategy for qualitative and quantitative analysis in proteomics based on signature peptides" <i>J. of Chromatography B</i> 745:197-210 (2000)	
	C10	Wang et al. "Proteomics based on selecting and quantifying cysteine containing peptides by covalent chromatography" <i>J. of Chromatography A</i> 924:345-357 (2001)	
	C11	Geng et al. "Signature-peptide approach to detecting proteins in complex mixtures" <i>J. of Chromatography A</i> 870:295-313 (2000)	
	C12	Yao et al. "Proteolytic <sup>18</sup> O Labeling for Comparative Proteomics: Model Studies with Two Serotypes of Adenovirus" <i>Anal. Chem.</i> 73:2836-2842 (2001)	
✓	C13	Conrads et al. "Quantitative Analysis of Bacterial and Mammalian Proteomes Using a Combination of Cysteine Affinity Tags and <sup>15</sup> N-Metabolic Labeling" <i>Anal. Chem.</i> 73:2132-2139 (2001)	

Examiner Signature	<i>David J. Venci</i>	Date Considered	2/27/06
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<b>Notice of References Cited</b>	Application/Control No. 10/621,958		Applicant(s)/Patent Under Reexamination LOCKE ET AL.	
	Examiner David J. Venci		Art Unit 1641	Page 1 of 1

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-5,760,394	06-1998	Welle, Richard P.	250/303
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.